Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Non-small Cell Lung Cancer
Related studies linked through entity extraction aliases.
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
- Status
- RECRUITING
- Phase
- NA
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
- Status
- WITHDRAWN
- Phase
- PHASE3
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Test-retest Evaluation of [18F]F-AraG PET
- Status
- RECRUITING
- Phase
- PHASE2
PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE1
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- Status
- RECRUITING
- Phase
- PHASE3
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain
- Status
- RECRUITING
- Phase
- N/A
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
CX3CR1+T Cell Predict Immunotherapy Efficacy
- Status
- COMPLETED
- Phase
- N/A
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1